{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:16:53Z","timestamp":1783574213635,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["ZIA BC 011513"],"award-info":[{"award-number":["ZIA BC 011513"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 3 (HER3), a member of the HER\/ErbB family, is broadly expressed across major breast cancer subtypes and contributes to tumor initiation, progression, and therapy resistance. Although numerous HER3-directed therapies have been evaluated in preclinical and clinical settings, limited efficacy and safety concerns have prevented any from achieving clinical approval. Near-infrared photoimmunotherapy (NIR-PIT) is a modality that selectively kills antibody-bound target cells upon NIR irradiation. In this study, we evaluated HER3-targeted NIR-PIT in breast cancer cell lines in vitro and in xenograft mouse models in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Triple-negative (MDA-MB-468) and Luminal (MCF-7) breast cancer cells were utilized. In vitro, the therapeutic efficacy of HER3-targeted NIR-PIT was assessed by monitoring morphological changes via differential interference contrast microscopy and evaluating cell cytotoxicity using propidium iodide staining. In vivo, MDA-MB-468 and MCF-7 were subcutaneously xenografted into nude mice. Mice bearing MDA-MB-468 tumors were assigned to Control, HER3 antibody-photoabsorber conjugate i.v., and HER3-targeted NIR-PIT groups, while MCF-7 tumor-bearing mice were divided into Control and HER3-targeted NIR-PIT groups. Tumor growth and survival rates were monitored, and histological alterations post-NIR-PIT were analyzed using Hematoxylin and eosin (H&amp;E) and pan-cytokeratin immunohistochemical staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HER3-targeted NIR-PIT induced robust cancer cell death in vitro, significantly suppressed tumor growth and prolonged survival in vivo, and achieved complete responses in 30% of treated mice bearing triple-negative breast cancer xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support HER3-targeted NIR-PIT as a promising therapeutic strategy for HER3-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16170-4","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:46:14Z","timestamp":1779108374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7659-1238","authenticated-orcid":false,"given":"Makoto","family":"Kano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-4112","authenticated-orcid":false,"given":"Hisataka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"23","key":"16170_CR1","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1073\/pnas.86.23.9193","volume":"86","author":"MH Kraus","year":"1989","unstructured":"Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB\/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A. 1989;86(23):9193\u20137. https:\/\/doi.org\/10.1073\/pnas.86.23.9193.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"16170_CR2","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1073\/pnas.87.13.4905","volume":"87","author":"GD Plowman","year":"1990","unstructured":"Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A. 1990;87(13):4905\u20139. https:\/\/doi.org\/10.1073\/pnas.87.13.4905.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"16170_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","volume":"41","author":"L Gandullo-S\u00e1nchez","year":"2022","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A HER3 in cancer: from the bench to the bedside. J Exp Clin Cancer Res. 2022;41(1):310. https:\/\/doi.org\/10.1186\/s13046-022-02515-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"16170_CR4","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1073\/pnas.91.17.8132","volume":"91","author":"PM Guy","year":"1994","unstructured":"Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A. 1994;91(17):8132\u20136. https:\/\/doi.org\/10.1073\/pnas.91.17.8132.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"16170_CR5","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","volume":"27","author":"HM Haikala","year":"2021","unstructured":"Haikala HM, J\u00e4nne PA. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Clin Cancer Res. 2021;27(13):3528\u2013910. .1158\/1078\u2009\u2013\u20090432.Ccr-20-4465.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"16170_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/path.1370","volume":"200","author":"CJ Witton","year":"2003","unstructured":"Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200(3):290. https:\/\/doi.org\/10.1002\/path.1370.","journal-title":"J Pathol"},{"issue":"8","key":"16170_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.bjc.6602184","volume":"91","author":"DM Abd El-Rehim","year":"2004","unstructured":"Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, et al Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004;91(8):1532\u201342. https:\/\/doi.org\/10.1038\/sj.bjc.6602184.","journal-title":"Br J Cancer"},{"issue":"3","key":"16170_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10549-013-2570-6","volume":"139","author":"SY La Bae","year":"2013","unstructured":"Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, et al HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat. 2013;139(3):741\u201350. https:\/\/doi.org\/10.1007\/s10549-013-2570-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"16170_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.breast.2014.06.011","volume":"23","author":"AS Berghoff","year":"2014","unstructured":"Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, et al. Co-overexpression of HER2\/HER3 is a predictor of impaired survival in breast cancer patients. Breast. 2014;23(5):637\u201343. https:\/\/doi.org\/10.1016\/j.breast.2014.06.011.","journal-title":"Breast"},{"issue":"1","key":"16170_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/s12885-018-4917-1","volume":"18","author":"S Luhtala","year":"2018","unstructured":"Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. BMC Cancer. 2018;18(1):1045. https:\/\/doi.org\/10.1186\/s12885-018-4917-1.","journal-title":"BMC Cancer"},{"issue":"1","key":"16170_CR11","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.clbc.2023.09.013","volume":"24","author":"M Hassanzadeh Makoui","year":"2024","unstructured":"Hassanzadeh Makoui M, Mobini M, Fekri S, Geranpayeh L, Moradi Tabriz H, Madjd Z, et al. Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer. Clin Breast Cancer. 2024;24(1):e9. https:\/\/doi.org\/10.1016\/j.clbc.2023.09.013.","journal-title":"Clin Breast Cancer"},{"key":"16170_CR12","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.ejca.2024.115081","volume":"213","author":"DW Lee","year":"2024","unstructured":"Lee DW, Ryu HS, Nikas IP, Koh J, Kim TY, Kim HK, et al Immune marker expression and prognosis of early breast cancer expressing HER3. Eur J Cancer. 2024;213:115081. https:\/\/doi.org\/10.1016\/j.ejca.2024.115081.","journal-title":"Eur J Cancer"},{"issue":"1","key":"16170_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-024-01859-w","volume":"26","author":"N Sinevici","year":"2024","unstructured":"Sinevici N, Edmonds CE, Dontchos BN, Wang G, Lehman CD, Isakoff S, Mahmood U A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance. Breast Cancer Res. 2024;26(1):107. https:\/\/doi.org\/10.1186\/s13058-024-01859-w.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"16170_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.5114\/wo.2013.38564","volume":"17","author":"J Czopek","year":"2013","unstructured":"Czopek J, Pawl\u0119ga J, Fijorek K, P\u00fcsk\u00fcll\u00fco\u011flu M, R\u00f3\u017canowski P, Oko\u0144 K HER-3 expression in HER-2-amplified breast carcinoma. Contemp Oncol (Pozn). 2013;17(5):446\u20139. https:\/\/doi.org\/10.5114\/wo.2013.38564.","journal-title":"Contemp Oncol (Pozn)"},{"key":"16170_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.5604\/17322693.1151339","volume":"69","author":"S D\u0119bska-Szmich","year":"2015","unstructured":"D\u0119bska-Szmich S, Kusi\u0144ska R, Czernek U, Szyd\u0142owska-Pazera K, Habib-Lisik M, Piekarski JH, et al Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer. Postepy Hig Med Dosw (Online). 2015;69:586\u201397. https:\/\/doi.org\/10.5604\/17322693.1151339.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"3","key":"16170_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41416-019-0670-8","volume":"122","author":"A Ho-Pun-Cheung","year":"2020","unstructured":"Ho-Pun-Cheung A, Bazin H, Boissi\u00e8re-Michot F, Mollevi C, Simony-Lafontaine J, Landas E, et al Quantification of HER1, HER2 and HER3 by time-resolved F\u00f6rster resonance energy transfer in FFPE triple-negative breast cancer samples. Br J Cancer. 2020;122(3):397\u2013404. https:\/\/doi.org\/10.1038\/s41416-019-0670-8.","journal-title":"Br J Cancer"},{"issue":"1","key":"16170_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12935-023-03055-w","volume":"23","author":"H Lyu","year":"2023","unstructured":"Lyu H, Shen F, Ruan S, Tan C, Zhou J, Thor AD, Liu B HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel. Cancer Cell Int. 2023;23(1):204. https:\/\/doi.org\/10.1186\/s12935-023-03055-w.","journal-title":"Cancer Cell Int"},{"issue":"17","key":"16170_CR18","doi-asserted-by":"publisher","first-page":"7692","DOI":"10.1073\/pnas.1002753107","volume":"107","author":"F Shi","year":"2010","unstructured":"Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A. 2010;107(17):7692\u20137. https:\/\/doi.org\/10.1073\/pnas.1002753107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"16170_CR19","doi-asserted-by":"publisher","first-page":"103390cells1221","DOI":"10.3390\/cells12212517","volume":"12","author":"A Majumder","year":"2023","unstructured":"Majumder A. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer. Cells. 2023;12(21):103390cells12212517.","journal-title":"Cells"},{"key":"16170_CR20","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/0008-5472.CAN-12-2868","volume":"73","author":"C Mirschberger","year":"2013","unstructured":"Mirschberger C, Schiller CB, Schraml M, Dimoudis N, Friess T, Gerdes CA, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013;73:5183\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2868.","journal-title":"Cancer Res"},{"issue":"6","key":"16170_CR21","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-20-0907","volume":"20","author":"M Hong","year":"2021","unstructured":"Hong M, Yoo Y, Kim M, Kim JY, Cha JS, Choi MK, et al. A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization. Mol Cancer Ther. 2021;20(6):1142\u201352. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0907.","journal-title":"Mol Cancer Ther"},{"key":"16170_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1074\/jbc.RA118.004420","volume":"294","author":"JP Turowec","year":"2019","unstructured":"Turowec JP, Lau EWT, Wang X, Brown KR, Fellouse FA, Jawanda KK, et al. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. J Biol Chem. 2019;294:1396\u2013409. https:\/\/doi.org\/10.1074\/jbc.RA118.004420.","journal-title":"J Biol Chem"},{"issue":"11","key":"16170_CR23","doi-asserted-by":"publisher","first-page":"e112376","DOI":"10.1371\/journal.pone.0112376","volume":"9","author":"JW D\u2019Souza","year":"2014","unstructured":"D\u2019Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, et al. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS ONE. 2014;9(11):e112376. https:\/\/doi.org\/10.1371\/journal.pone.0112376.","journal-title":"PLoS ONE"},{"issue":"18","key":"16170_CR24","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-14-3312","volume":"21","author":"HJ Jacobsen","year":"2015","unstructured":"Jacobsen HJ, Poulsen TT, Dahlman A, Kjaer I, Koefoed K, Sen JW, et al. Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clin Cancer Res. 2015;21(18):4110\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3312.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"16170_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","volume":"33","author":"CAW Geuijen","year":"2018","unstructured":"Geuijen CAW, De Nardis C, Maussang D, Rovers E, Gallenne T, Hendriks LJA, et al. Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. Cancer Cell. 2018;33(5):922\u2013e3610. https:\/\/doi.org\/10.1016\/j.ccell.2018.04.003.","journal-title":"Cancer Cell"},{"issue":"4","key":"16170_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccell.2011.09.003","volume":"20","author":"G Schaefer","year":"2011","unstructured":"Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. 2011;20(4):472\u201386. https:\/\/doi.org\/10.1016\/j.ccell.2011.09.003.","journal-title":"Cancer Cell"},{"issue":"5","key":"16170_CR27","doi-asserted-by":"publisher","first-page":"110285","DOI":"10.1016\/j.celrep.2021.110285","volume":"38","author":"MR Campbell","year":"2022","unstructured":"Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, et al Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022;38(5):110285. https:\/\/doi.org\/10.1016\/j.celrep.2021.110285.","journal-title":"Cell Rep"},{"issue":"23","key":"16170_CR28","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.Ccr-19-1745","volume":"25","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, et al. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clin Cancer Res. 2019;25(23):7151\u201361 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1745.","journal-title":"Clin Cancer Res"},{"key":"16170_CR29","doi-asserted-by":"publisher","unstructured":"J\u00e4nne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M et al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022;12(1):74-89 https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0715.","DOI":"10.1158\/2159-8290.Cd-21-0715"},{"issue":"36","key":"16170_CR30","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/jco.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial. J Clin Oncol. 2023;41(36):5550\u201360. https:\/\/doi.org\/10.1200\/jco.23.00882.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16170_CR31","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","volume":"52","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Choyke PL Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019;52(8):2332\u20139. https:\/\/doi.org\/10.1021\/acs.accounts.9b00273.","journal-title":"Acc Chem Res"},{"issue":"12","key":"16170_CR32","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","volume":"17","author":"M Mitsunaga","year":"2011","unstructured":"Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685\u201391. https:\/\/doi.org\/10.1038\/nm.2554.","journal-title":"Nat Med"},{"key":"16170_CR33","doi-asserted-by":"publisher","first-page":"1008162","DOI":"10.3389\/fonc.2022.1008162","volume":"12","author":"A Furusawa","year":"2022","unstructured":"Furusawa A, Choyke PL, Kobayashi H NIR-PIT: Will it become a standard cancer treatment? Front Oncol. 2022;12:1008162. https:\/\/doi.org\/10.3389\/fonc.2022.1008162.","journal-title":"Front Oncol"},{"issue":"8","key":"16170_CR34","doi-asserted-by":"publisher","first-page":"e0136829","DOI":"10.1371\/journal.pone.0136829","volume":"10","author":"T Nagaya","year":"2015","unstructured":"Nagaya T, Sato K, Harada T, Nakamura Y, Choyke PL, Kobayashi H Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS ONE. 2015;10(8):e0136829. https:\/\/doi.org\/10.1371\/journal.pone.0136829.","journal-title":"PLoS ONE"},{"issue":"4","key":"16170_CR35","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1002\/cam4.5302","volume":"12","author":"S Yamashita","year":"2023","unstructured":"Yamashita S, Kojima M, Onda N, Yoshida T, Shibutani M Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. Cancer Med. 2023;12(4):4579\u201389. https:\/\/doi.org\/10.1002\/cam4.5302.","journal-title":"Cancer Med"},{"issue":"10","key":"16170_CR36","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1021\/acs.bioconjchem.9b00547","volume":"30","author":"R Okada","year":"2019","unstructured":"Okada R, Maruoka Y, Furusawa A, Inagaki F, Nagaya T, Fujimura D, et al The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. Bioconjug Chem. 2019;30(10):2624\u201333. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00547.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"16170_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500x.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303\u20136. https:\/\/doi.org\/10.4103\/0976-500x.119726.","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"16170_CR38","first-page":"35","volume":"1","author":"R Behzadi","year":"2015","unstructured":"Behzadi R, Fattahi S, Momtaz MR, Kavoosian S, Asouri M, Akhavan-Niaki H. Injectable Estradiol Valerate, as a Substitute for Estradiol Pellets in Breast Cancer Animal Model. Int Biol Biomedical J. 2015;1(1):35\u20138.","journal-title":"Int Biol Biomedical J"},{"key":"16170_CR39","doi-asserted-by":"publisher","unstructured":"Kato T, Okada R, Furusawa A, Inagaki F, Wakiyama H, Furumoto H et al. Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021;20(11):2262-73 https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0470.","DOI":"10.1158\/1535-7163.Mct-21-0470"},{"key":"16170_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/1471-2407-12-345","volume":"12","author":"M Mitsunaga","year":"2012","unstructured":"Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012;12:345. https:\/\/doi.org\/10.1186\/1471-2407-12-345.","journal-title":"BMC Cancer"},{"issue":"21","key":"16170_CR41","doi-asserted-by":"publisher","first-page":"103390cancers15","DOI":"10.3390\/cancers15215117","volume":"15","author":"NL Miyazaki","year":"2023","unstructured":"Miyazaki NL, Furusawa A, Choyke PL, Kobayashi H. Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and\/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2023;15(21):103390cancers15215117.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"16170_CR42","doi-asserted-by":"publisher","first-page":"188789","DOI":"10.1016\/j.bbcan.2022.188789","volume":"1877","author":"X Li","year":"2022","unstructured":"Li X, Zhao L, Chen C, Nie J, Jiao B Can EGFR be a therapeutic target in breast cancer? Biochim Biophys Acta Rev Cancer. 2022;1877(5):188789. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188789.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"16170_CR43","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1172\/jci66764","volume":"123","author":"MM Morrison","year":"2013","unstructured":"Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, et al ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013;123(10):4329\u201343. https:\/\/doi.org\/10.1172\/jci66764.","journal-title":"J Clin Invest"},{"issue":"1","key":"16170_CR44","doi-asserted-by":"publisher","first-page":"2540599","DOI":"10.1080\/07853890.2025.2540599","volume":"57","author":"A Furusawa","year":"2025","unstructured":"Furusawa A, Takao S, Suzuki M, Kano M, Yamamoto H, Kano M, et al. EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer. Ann Med. 2025;57(1):2540599.","journal-title":"Ann Med"},{"issue":"7126","key":"16170_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437\u201341. https:\/\/doi.org\/10.1038\/nature05474.","journal-title":"Nature"},{"issue":"6","key":"16170_CR46","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.Can-08-1056","volume":"69","author":"M Narayan","year":"2009","unstructured":"Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ Trastuzumab-induced HER reprogramming in resistant breast carcinoma cells. Cancer Res. 2009;69(6):2191\u20134. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-1056.","journal-title":"Cancer Res"},{"issue":"5","key":"16170_CR47","first-page":"356","volume":"24","author":"I Uberall","year":"2011","unstructured":"Uberall I, Kr\u00edzov\u00e1 K, Steigerov\u00e1 J. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells\u2013preliminary study. Klin Onkol. 2011;24(5):356\u201360.","journal-title":"Klin Onkol"},{"issue":"6","key":"16170_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.7150\/thno.5908","volume":"3","author":"T Nakajima","year":"2013","unstructured":"Nakajima T, Sano K, Choyke PL, Kobayashi H Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013;3(6):357\u201365. https:\/\/doi.org\/10.7150\/thno.5908.","journal-title":"Theranostics"},{"key":"16170_CR49","doi-asserted-by":"publisher","unstructured":"Siddiqui MR, Railkar R, Sanford T, Crooks DR, Eckhaus MA, Haines D et al Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Sci Rep. 2019;9(1):2084. https:\/\/doi.org\/10.1038\/s41598-019-38575-x.","DOI":"10.1038\/s41598-019-38575-x"},{"issue":"3","key":"16170_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2326-6066.CIR-18-0546","volume":"7","author":"T Nagaya","year":"2019","unstructured":"Nagaya T, Friedman J, Maruoka Y, Ogata F, Okuyama S, Clavijo PE, et al. Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors. Cancer Immunol Res. 2019;7(3):401\u201313. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0546.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"16170_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.lungcan.2015.03.010","volume":"88","author":"M Nishio","year":"2015","unstructured":"Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, et al Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer. 2015;88(3):275\u201381. https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.010.","journal-title":"Lung Cancer"},{"issue":"7","key":"16170_CR52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1080\/19420862.2016.1212147","volume":"8","author":"M Malm","year":"2016","unstructured":"Malm M, Frejd FY, St\u00e5hl S, L\u00f6fblom J Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs. 2016;8(7):1195\u2013209. https:\/\/doi.org\/10.1080\/19420862.2016.1212147.","journal-title":"MAbs"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16170-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:31:16Z","timestamp":1783571476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16170-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16170"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16170-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the local Animal Care and Use Committee (MIP-003\u20134).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}